Compare Global X SuperDividend ETF (SDIV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs Viatris Inc — how do they compare? Global X SuperDividend ETF trades at $23.82 (market cap $1.17B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 17.1× Global X SuperDividend ETF's market cap, and Viatris Inc pays a 2.75% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 47 Days and Viatris Inc for 57 Days on average.
| SDIV | VTRS | |
|---|---|---|
Market Cap | $1.17B | $20.03B |
Volume | 387,692 | 14,109,977 |
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $18.27 |
52-Week Low | $22.90 | $9.74 |
Typical Hold Time | 47 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $23.58, down 0.55% with a bearish technical signal from moving averages. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, having lost 66% since inception. Recent institutional buying by Ameritas Advisory contrasts with negative media coverage questioning sustainability of high yields amid capital depreciation.
Outlook remains challenged by structural underperformance versus benchmarks. The high yield attracts income seekers but masks negative growth and volatility risks. Investment case hinges on yield sustainability versus capital preservation, with analyst sentiment cautious given persistent track record of value destruction.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
